Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.

A coalition of health care companies working to bring down the cost of drugs is now targeting insulin for diabetics, and insurance company Florida Blue will join them.